The launching official ceremony was held at the Four Season Hotel in Syria and was attended by fifty doctors specializing in diabetes, representatives of the Health Ministry, the Syrian Diabetic Foot Association and the Cuban Ambassador in Syria Luis Mariano Fernandez.

In statements to Prensa Latina, Ammar Matouk, member of the Maatouk Consortium Board of Directors, which brings together several companies including Maatouk Drugstores. Matouk stated the Cuban product is the only one of its kind worldwide and has just arrived in Syria after four years of hard work which included registering the product and overcoming several difficulties. We hope to increase Cuba´s imported drugs, since Heberprot-p has a positive impact, and we intend not only to treat patients in Syria but also in other regional nations, Matouk stressed.

Regarding the possibility of producing Cuban drugs in Syria, Matouk said that Cuba has advanced in biotechnological products, and even though Syria now has 95 drug plants, it does not reach Cuba´s technology level.

U.S. blockade prevents and delays the arrival of those products to Syria, so we will continue importing those medicines from Cuba, the businessman asserted.

In turn, advisor Mohanad Ali praised Heberprot-p´s successful clinical trials in several countries around the globe and hoped the results will be the same in Syria.

In his speech, the Cuban ambassador said Heberprot-p´s arrival in Syria as a recognition of the efforts of Cuban scientists to create a unique drug at the service of humanity.

pll/ro/fm